NFKB1 and prostate cancer: We have also reported that CDDOs inhibit the progression of the carcinoma of the prostate (CaP) in the TRAMP mouse model of prostate cancer through the inhibition of antiapoptotic Akt and NF-κB signaling proteins [20,21].